Duyuru • Jun 01
Samrat Pharmachem Limited, Annual General Meeting, Sep 23, 2026 Samrat Pharmachem Limited, Annual General Meeting, Sep 23, 2026. New Risk • Jun 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 33% per year over the past 5 years. Market cap is less than US$10m (₹656.7m market cap, or US$6.92m). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change). Reported Earnings • Jun 01
Full year 2026 earnings released: ₹10.72 loss per share (vs ₹23.02 profit in FY 2025) Full year 2026 results: ₹10.72 loss per share (down from ₹23.02 profit in FY 2025). Revenue: ₹2.91b (up 1.6% from FY 2025). Net loss: ₹33.1m (down 147% from profit in FY 2025). Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. Duyuru • Mar 25
Samrat Pharmachem Limited to Report Fiscal Year 2026 Results on May 30, 2026 Samrat Pharmachem Limited announced that they will report fiscal year 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026 Reported Earnings • Feb 15
Third quarter 2026 earnings released: ₹1.49 loss per share (vs ₹9.01 profit in 3Q 2025) Third quarter 2026 results: ₹1.49 loss per share (down from ₹9.01 profit in 3Q 2025). Revenue: ₹638.3m (flat on 3Q 2025). Net loss: ₹4.60m (down 117% from profit in 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 45 percentage points per year, which is a significant difference in performance. Buy Or Sell Opportunity • Feb 10
Now 20% overvalued Over the last 90 days, the stock has fallen 11% to ₹245. The fair value is estimated to be ₹204, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 71%. Valuation Update With 7 Day Price Move • Feb 09
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹238, the stock trades at a trailing P/E ratio of 46.8x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 57% over the past three years. Duyuru • Dec 29
Samrat Pharmachem Limited to Report Q3, 2026 Results on Feb 13, 2026 Samrat Pharmachem Limited announced that they will report Q3, 2026 results on Feb 13, 2026 New Risk • Nov 17
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.5% Last year net profit margin: 2.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 12% per year over the past 5 years. Market cap is less than US$10m (₹842.1m market cap, or US$9.50m). Minor Risk Profit margins are more than 30% lower than last year (0.5% net profit margin). New Risk • Oct 27
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹879.9m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 4.3% per year over the past 5 years. Market cap is less than US$10m (₹879.9m market cap, or US$9.97m). Minor Risk Paying a dividend despite having no free cash flows. Duyuru • Sep 27
Samrat Pharmachem Limited Appoints Piyush Dharod as Non-Executive Independent Director Samrat Pharmachem Limited at its AGM held on September 25, 2025, approved appointment of Mr. Piyush Dharod (DIN: 11119391) as Non-Executive Independent Director of the Company. Duyuru • Sep 26
Samrat Pharmachem Limited to Report Q2, 2026 Results on Nov 14, 2025 Samrat Pharmachem Limited announced that they will report Q2, 2026 results on Nov 14, 2025 Upcoming Dividend • Sep 11
Upcoming dividend of ₹1.00 per share Eligible shareholders must have bought the stock before 18 September 2025. Payment date: 24 October 2025. Payout ratio is a comfortable 4.3% but the company is not cash flow positive. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%). Reported Earnings • Aug 15
First quarter 2026 earnings released: ₹0.74 loss per share (vs ₹6.69 profit in 1Q 2025) First quarter 2026 results: ₹0.74 loss per share (down from ₹6.69 profit in 1Q 2025). Revenue: ₹763.4m (down 6.2% from 1Q 2025). Net loss: ₹2.29m (down 111% from profit in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 47 percentage points per year, which is a significant difference in performance. Duyuru • Jul 02
Samrat Pharmachem Limited Announces Resignation of Renu Dharod as Director, Effective 30 June 2025 Samrat Pharmachem Limited announced that Ms. Renu Dharod (DIN: 07063088), has tendered her resignation as the Independent Director of the Company, with effect from close of business hours on 30th June, 2025, citing pre-occupation and other personal commitments. Consequently, she shall also cease to be the Chairman of the Corporate Social Responsibility Committee, Stakeholders Relationship Committee and Risk Management Committee and Member of the Audit Committee, Nomination & Remuneration Committee & Health, Safety and Sustainability Committee of the Company. Duyuru • Jun 23
Samrat Pharmachem Limited to Report Q1, 2026 Results on Aug 13, 2025 Samrat Pharmachem Limited announced that they will report Q1, 2026 results on Aug 13, 2025 Duyuru • Jun 02
Samrat Pharmachem Limited, Annual General Meeting, Sep 25, 2025 Samrat Pharmachem Limited, Annual General Meeting, Sep 25, 2025. New Risk • Jun 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (24% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₹1.08b market cap, or US$12.7m). Reported Earnings • Jun 02
Full year 2025 earnings released: EPS: ₹23.02 (vs ₹7.00 in FY 2024) Full year 2025 results: EPS: ₹23.02 (up from ₹7.00 in FY 2024). Revenue: ₹2.87b (up 1.8% from FY 2024). Net income: ₹71.1m (up 229% from FY 2024). Profit margin: 2.5% (up from 0.8% in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance. Duyuru • May 30
Samrat Pharmachem Limited Recommends Dividend for Fiscal Year 2024-25, Payable on or Before October 24, 2025 Samrat Pharmachem Limited at its meeting held on May 30, 2025 recommended Dividend at 10% on paid-up capital of the company. Record Date: September 18, 2025, The Company has fixed September 18, 2025, as the Record Date for the purpose of determining the Members eligible to receive dividend of INR 1.00 per equity share for Fiscal Year 2024-25. The dividend, if approved at the 33rd Annual General Meeting, shall be paid on or before October 24, 2025. Valuation Update With 7 Day Price Move • May 15
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹390, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 26x in the Chemicals industry in India. Negligible returns to shareholders over past three years. Valuation Update With 7 Day Price Move • Apr 22
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to ₹405, the stock trades at a trailing P/E ratio of 14.1x. Average trailing P/E is 25x in the Chemicals industry in India. Total loss to shareholders of 22% over the past three years. Duyuru • Mar 26
Samrat Pharmachem Limited to Report Fiscal Year 2025 Results on May 30, 2025 Samrat Pharmachem Limited announced that they will report fiscal year 2025 results on May 30, 2025 Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹386, the stock trades at a trailing P/E ratio of 13.4x. Average trailing P/E is 25x in the Chemicals industry in India. Total loss to shareholders of 16% over the past three years. Reported Earnings • Feb 15
Third quarter 2025 earnings released: EPS: ₹9.01 (vs ₹1.11 in 3Q 2024) Third quarter 2025 results: EPS: ₹9.01 (up from ₹1.11 in 3Q 2024). Revenue: ₹636.7m (up 3.2% from 3Q 2024). Net income: ₹27.8m (up ₹24.4m from 3Q 2024). Profit margin: 4.4% (up from 0.6% in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Duyuru • Dec 31
Samrat Pharmachem Limited to Report Fiscal Year 2024 Results on Feb 14, 2025 Samrat Pharmachem Limited announced that they will report fiscal year 2024 results on Feb 14, 2025 Reported Earnings • Nov 16
Second quarter 2025 earnings released: EPS: ₹8.61 (vs ₹0.61 loss in 2Q 2024) Second quarter 2025 results: EPS: ₹8.61 (up from ₹0.61 loss in 2Q 2024). Revenue: ₹706.6m (down 11% from 2Q 2024). Net income: ₹26.6m (up ₹28.5m from 2Q 2024). Profit margin: 3.8% (up from net loss in 2Q 2024). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings. Duyuru • Sep 27
Samrat Pharmachem Limited to Report First Half, 2025 Results on Nov 14, 2024 Samrat Pharmachem Limited announced that they will report first half, 2025 results on Nov 14, 2024 New Risk • Sep 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Profit margins are more than 30% lower than last year (1.2% net profit margin). Market cap is less than US$100m (₹1.71b market cap, or US$20.5m). Buy Or Sell Opportunity • Sep 16
Now 27% overvalued after recent price rise Over the last 90 days, the stock has risen 86% to ₹632. The fair value is estimated to be ₹498, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has declined by 33%. Valuation Update With 7 Day Price Move • Sep 12
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹506, the stock trades at a trailing P/E ratio of 43.2x. Average trailing P/E is 36x in the Chemicals industry in India. Total returns to shareholders of 152% over the past three years. Duyuru • Sep 04
Samrat Pharmachem Limited Proposes Dividend for Fiscal Year 2023-24, Payable on or Before October 25, 2024 Samrat Pharmachem Limited has fixed September 19, 2024, as the Record Date for the purpose of determining the Members eligible to receive dividend of INR 1.00/- per equity share for FY2023-24. The dividend, if approved at the 32nd Annual General Meeting, shall be paid on or before October 25, 2024. Valuation Update With 7 Day Price Move • Aug 23
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹462, the stock trades at a trailing P/E ratio of 39.4x. Average trailing P/E is 35x in the Chemicals industry in India. Total returns to shareholders of 133% over the past three years. Reported Earnings • Aug 14
First quarter 2025 earnings released: EPS: ₹6.68 (vs ₹1.98 in 1Q 2024) First quarter 2025 results: EPS: ₹6.68 (up from ₹1.98 in 1Q 2024). Revenue: ₹814.1m (up 42% from 1Q 2024). Net income: ₹20.7m (up 238% from 1Q 2024). Profit margin: 2.5% (up from 1.1% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings. Duyuru • Jul 05
Samrat Pharmachem Limited Announces Director Resignations Samrat Pharmachem Limited informed about the following changes composition of the Board: Mr. Mahendra Pipalia (DIN: 00216959), has tendered his resignation as the Independent Director of the Company, with effect from close of business hours on 28th June, 2024, citing pre-occupation and other personal commitments. Consequently, he shall also cease to be the Chairman of the Audit Committee and Member of the Nomination & Remuneration Committee, Stakeholders Relationship Committee, Risk Management Committee, Corporate Social Responsibility Committee & Health, Safety and Sustainability Committee of the Company. Mr. Samir Kothary (DIN: 00216603), has tendered his resignation as the Independent Director of the Company, with effect from close of business hours on 28th June, 2024, citing pre-occupation and other personal commitments. Consequently, he shall also cease to be the Chairman of the Nomination & Remuneration Committee, Health, Safety and Sustainability Committee and Member of the Audit Committee, Stakeholders Relationship Committee, Risk Management Committee and Corporate Social Responsibility Committee of the Company. Duyuru • Jun 30
Samrat Pharmachem Limited to Report Q1, 2025 Results on Aug 13, 2024 Samrat Pharmachem Limited announced that they will report Q1, 2025 results on Aug 13, 2024 Reported Earnings • Jun 04
Full year 2024 earnings released: EPS: ₹7.00 (vs ₹53.83 in FY 2023) Full year 2024 results: EPS: ₹7.00 (down from ₹53.83 in FY 2023). Revenue: ₹2.83b (down 8.9% from FY 2023). Net income: ₹21.6m (down 87% from FY 2023). Profit margin: 0.8% (down from 5.4% in FY 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Declared Dividend • Jun 01
Dividend of ₹1.00 announced Dividend of ₹1.00 is the same as last year. Ex-date: 19th September 2024 Payment date: 26th October 2024 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (2% earnings payout ratio) and cash flows (5% cash payout ratio). The dividend has not increased over the past 2 years but payments have been stable during that time. The company's earnings per share (EPS) would need to decline by 98% to shift the payout ratio to a potentially unsustainable range, which is more than the 53% EPS decline seen over the last 5 years. Duyuru • May 31
Samrat Pharmachem Limited, Annual General Meeting, Sep 26, 2024 Samrat Pharmachem Limited, Annual General Meeting, Sep 26, 2024. Duyuru • Mar 29
Samrat Pharmachem Limited to Report Q4, 2024 Results on May 30, 2024 Samrat Pharmachem Limited announced that they will report Q4, 2024 results at 3:30 PM, Indian Standard Time on May 30, 2024 Reported Earnings • Feb 15
Third quarter 2024 earnings released: EPS: ₹1.11 (vs ₹6.78 in 3Q 2023) Third quarter 2024 results: EPS: ₹1.11 (down from ₹6.78 in 3Q 2023). Revenue: ₹620.9m (down 26% from 3Q 2023). Net income: ₹3.44m (down 84% from 3Q 2023). Profit margin: 0.6% (down from 2.5% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Dec 30
Samrat Pharmachem Limited to Report Q3, 2023 Results on Feb 14, 2024 Samrat Pharmachem Limited announced that they will report Q3, 2023 results at 3:30 PM, Indian Standard Time on Feb 14, 2024 Reported Earnings • Nov 10
Second quarter 2024 earnings released: ₹0.61 loss per share (vs ₹19.14 profit in 2Q 2023) Second quarter 2024 results: ₹0.61 loss per share (down from ₹19.14 profit in 2Q 2023). Revenue: ₹800.4m (up 13% from 2Q 2023). Net loss: ₹1.88m (down 103% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Sep 27
Samrat Pharmachem Limited to Report Q2, 2024 Results on Nov 08, 2023 Samrat Pharmachem Limited announced that they will report Q2, 2024 results on Nov 08, 2023 Upcoming Dividend • Sep 11
Upcoming dividend of ₹1.00 per share at 0.2% yield Eligible shareholders must have bought the stock before 18 September 2023. Payment date: 24 October 2023. Payout ratio is a comfortable 1.9% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.8%). Valuation Update With 7 Day Price Move • Aug 23
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹418, the stock trades at a trailing P/E ratio of 16.4x. Average trailing P/E is 26x in the Chemicals industry in India. Total returns to shareholders of 225% over the past three years. Reported Earnings • Aug 15
First quarter 2024 earnings released: EPS: ₹1.98 (vs ₹30.32 in 1Q 2023) First quarter 2024 results: EPS: ₹1.98 (down from ₹30.32 in 1Q 2023). Revenue: ₹578.4m (down 33% from 1Q 2023). Net income: ₹6.11m (down 94% from 1Q 2023). Profit margin: 1.1% (down from 11% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 53% per year whereas the company’s share price has increased by 57% per year. Valuation Update With 7 Day Price Move • Aug 07
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹363, the stock trades at a trailing P/E ratio of 6.7x. Average trailing P/E is 24x in the Chemicals industry in India. Total returns to shareholders of 316% over the past three years. Valuation Update With 7 Day Price Move • Jul 05
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹508, the stock trades at a trailing P/E ratio of 9.4x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 446% over the past three years. Duyuru • Jul 01
Samrat Pharmachem Limited to Report Q1, 2024 Results on Aug 14, 2023 Samrat Pharmachem Limited announced that they will report Q1, 2024 results on Aug 14, 2023 Reported Earnings • Jun 02
Full year 2023 earnings released: EPS: ₹53.83 (vs ₹55.62 in FY 2022) Full year 2023 results: EPS: ₹53.83 (down from ₹55.62 in FY 2022). Revenue: ₹3.11b (up 40% from FY 2022). Net income: ₹166.3m (down 3.2% from FY 2022). Profit margin: 5.3% (down from 7.7% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has increased by 76% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Jun 01
Samrat Pharmachem Limited Recommends Dividend for the Financial Year Ended March 31, 2023 Samrat Pharmachem Limited at its board meeting held on May 30, 2023, recommended dividend of INR 1 per fully paid equity share of INR 10 each (10%) for the financial year ended March 31, 2023, subject to approval of the members at the upcoming Annual General Meeting of the Company. Duyuru • May 31
Samrat Pharmachem Limited, Annual General Meeting, Sep 28, 2023 Samrat Pharmachem Limited, Annual General Meeting, Sep 28, 2023. Agenda: Annual General Meeting. Valuation Update With 7 Day Price Move • Apr 06
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹430, the stock trades at a trailing P/E ratio of 5.4x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 420% over the past three years. Valuation Update With 7 Day Price Move • Mar 21
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹408, the stock trades at a trailing P/E ratio of 5.2x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 575% over the past three years. Reported Earnings • Feb 18
Third quarter 2023 earnings released: EPS: ₹6.78 (vs ₹20.87 in 3Q 2022) Third quarter 2023 results: EPS: ₹6.78 (down from ₹20.87 in 3Q 2022). Revenue: ₹839.9m (up 52% from 3Q 2022). Net income: ₹21.0m (down 68% from 3Q 2022). Profit margin: 2.5% (down from 12% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has increased by 86% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Dec 30
Samrat Pharmachem Limited to Report Q4, 2022 Results on Feb 14, 2023 Samrat Pharmachem Limited announced that they will report Q4, 2022 results at 3:30 PM, Indian Standard Time on Feb 14, 2023 Valuation Update With 7 Day Price Move • Dec 08
Investor sentiment improved over the past week After last week's 22% share price gain to ₹869, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 842% over the past three years. Valuation Update With 7 Day Price Move • Nov 21
Investor sentiment deteriorated over the past week After last week's 22% share price decline to ₹768, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 697% over the past three years. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Non-Independent Executive Director Megh Mehta was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Oct 01
Samrat Pharmachem Limited to Report Q2, 2023 Results on Nov 14, 2022 Samrat Pharmachem Limited announced that they will report Q2, 2023 results on Nov 14, 2022 Valuation Update With 7 Day Price Move • Sep 20
Investor sentiment improved over the past week After last week's 15% share price gain to ₹1,156, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 1,286% over the past three years. Valuation Update With 7 Day Price Move • Sep 05
Investor sentiment improved over the past week After last week's 22% share price gain to ₹885, the stock trades at a trailing P/E ratio of 10.7x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 996% over the past three years. Duyuru • Sep 03
Samrat Pharmachem Limited, Annual General Meeting, Sep 30, 2022 Samrat Pharmachem Limited, Annual General Meeting, Sep 30, 2022, at 14:00 Indian Standard Time. Valuation Update With 7 Day Price Move • Aug 16
Investor sentiment improved over the past week After last week's 20% share price gain to ₹545, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 587% over the past three years. Duyuru • Jul 01
Samrat Pharmachem Limited to Report Q1, 2023 Results on Aug 13, 2022 Samrat Pharmachem Limited announced that they will report Q1, 2023 results on Aug 13, 2022 Reported Earnings • Jun 01
Full year 2022 earnings released: EPS: ₹55.62 (vs ₹17.26 in FY 2021) Full year 2022 results: EPS: ₹55.62 (up from ₹17.26 in FY 2021). Revenue: ₹2.22b (up 24% from FY 2021). Net income: ₹171.8m (up 222% from FY 2021). Profit margin: 7.7% (up from 3.0% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has increased by 79% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • May 31
Samrat Pharmachem Limited Recommends Dividend for the Financial Year Ended March 31, 2022 Samrat Pharmachem Limited recommended dividend of INR 1/- per fully paid equity share of INR 10/- for the financial year ended March 31, 2022, subject to approval of members at the upcoming annual general meeting of the company. Valuation Update With 7 Day Price Move • May 06
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₹431, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 412% over the past three years. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Non-Independent Executive Director Megh Mehta was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Apr 09
Samrat Pharmachem Limited to Report Q4, 2022 Results on May 30, 2022 Samrat Pharmachem Limited announced that they will report Q4, 2022 results on May 30, 2022 Reported Earnings • Feb 13
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹20.87 (up from ₹4.97 in 3Q 2021). Revenue: ₹553.4m (flat on 3Q 2021). Net income: ₹64.5m (up 320% from 3Q 2021). Profit margin: 12% (up from 2.8% in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has increased by 104% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Jan 28
Investor sentiment deteriorated over the past week After last week's 17% share price decline to ₹426, the stock trades at a trailing P/E ratio of 19.3x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 608% over the past three years. Valuation Update With 7 Day Price Move • Dec 22
Investor sentiment improved over the past week After last week's 18% share price gain to ₹318, the stock trades at a trailing P/E ratio of 14.4x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 525% over the past three years. Reported Earnings • Nov 18
Second quarter 2022 earnings released: EPS ₹9.03 (vs ₹4.66 in 2Q 2021) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: ₹591.5m (up 43% from 2Q 2021). Net income: ₹27.9m (up 94% from 2Q 2021). Profit margin: 4.7% (up from 3.5% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Aug 23
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₹189, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 109% over the past three years. Reported Earnings • Aug 18
First quarter 2022 earnings released: EPS ₹3.09 (vs ₹2.58 in 1Q 2021) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2022 results: Revenue: ₹473.9m (up 34% from 1Q 2021). Net income: ₹9.54m (up 20% from 1Q 2021). Profit margin: 2.0% (down from 2.3% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 30% per year. Valuation Update With 7 Day Price Move • Jul 07
Investor sentiment improved over the past week After last week's 20% share price gain to ₹278, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 114% over the past three years. Reported Earnings • Jul 03
Full year 2021 earnings released: EPS ₹17.26 (vs ₹13.71 in FY 2020) The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: ₹1.79b (up 30% from FY 2020). Net income: ₹53.3m (up 26% from FY 2020). Profit margin: 3.0% (down from 3.1% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 25% per year whereas the company’s share price has increased by 22% per year. Valuation Update With 7 Day Price Move • Apr 24
Investor sentiment improved over the past week After last week's 30% share price gain to ₹187, the stock trades at a trailing P/E ratio of 18.6x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 23% over the past three years. Is New 90 Day High Low • Mar 01
New 90-day high: ₹152 The company is up 15% from its price of ₹133 on 01 December 2020. The Indian market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is up 11% over the same period. Valuation Update With 7 Day Price Move • Feb 18
Investor sentiment improved over the past week After last week's 19% share price gain to ₹145, the stock is trading at a trailing P/E ratio of 14.5x, up from the previous P/E ratio of 12.2x. This compares to an average P/E of 16x in the Chemicals industry in India. Total returns to shareholders over the past three years were flat. Reported Earnings • Feb 14
Third quarter 2021 earnings released: EPS ₹4.97 (vs ₹1.52 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹549.4m (up 56% from 3Q 2020). Net income: ₹15.4m (up 226% from 3Q 2020). Profit margin: 2.8% (up from 1.3% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Duyuru • Jan 14
Samrat Pharmachem Limited to Report Q3, 2021 Results on Feb 13, 2021 Samrat Pharmachem Limited announced that they will report Q3, 2021 results on Feb 13, 2021 Duyuru • Dec 05
Samrat Pharmachem Limited, Annual General Meeting, Dec 31, 2020 Samrat Pharmachem Limited, Annual General Meeting, Dec 31, 2020, at 13:00 Indian Standard Time. Agenda: To consider and receive the audited financial statements of the company for the year ended 31 March 2020, together with directors' and auditors' reports thereon; to consider re-appointments of directors in place of Mr. Megh Rajesh Mehta (DIN: 07287394), who retires by rotation and, being eligible, offers himself for re-appointment; and to consider other matters. Is New 90 Day High Low • Dec 01
New 90-day high: ₹133 The company is up 24% from its price of ₹107 on 02 September 2020. The Indian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 11% over the same period. Valuation Update With 7 Day Price Move • Dec 01
Market bids up stock over the past week After last week's 15% share price gain to ₹133, the stock is trading at a trailing P/E ratio of 13.2x, up from the previous P/E ratio of 11.5x. This compares to an average P/E of 16x in the Chemicals industry in India. Total returns to shareholders over the past three years are 67%. Reported Earnings • Nov 16
Second quarter 2021 earnings released: EPS ₹4.66 The company reported a soft second quarter result with weaker earnings and profit margins, although revenues were improved. Second quarter 2021 results: Revenue: ₹415.2m (up 12% from 2Q 2020). Net income: ₹14.4m (down 4.2% from 2Q 2020). Profit margin: 3.5% (down from 4.1% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Oct 26
Market bids up stock over the past week After last week's 16% share price gain to ₹130, the stock is trading at a trailing P/E ratio of 12.7x, up from the previous P/E ratio of 11x. This compares to an average P/E of 15x in the Chemicals industry in India. Total returns to shareholders over the past three years are 81%. Duyuru • Sep 09
Samrat Pharmachem Limited to Report Q1, 2020 Results on Sep 14, 2020 Samrat Pharmachem Limited announced that they will report Q1, 2020 results on Sep 14, 2020 Duyuru • Jul 18
Samrat Pharmachem Limited to Report Fiscal Year 2020 Results on Jul 31, 2020 Samrat Pharmachem Limited announced that they will report fiscal year 2020 results on Jul 31, 2020